Hansa Biopharma AB (publ) (STO: HNSA)
Sweden
· Delayed Price · Currency is SEK 38.88
+2.24 (6.11%)
Dec 20, 2024, 5:29 PM CET
Hansa Biopharma AB Employees
Hansa Biopharma AB had 168 employees as of December 31, 2023. The number of employees increased by 18 or 12.00% compared to the previous year.
Employees
168
Change (1Y)
18
Growth (1Y)
12.00%
Revenue / Employee
1.40M SEK
Profits / Employee
-4.85M SEK
Market Cap
2.64B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca PLC | 89,900 |
| Swedish Orphan Biovitrum AB (publ) | 1,772 |
| Sectra AB (publ) | 1,204 |
| Getinge AB (publ) | 11,739 |
| Camurus AB (publ) | 213 |
| Medicover AB (publ) | 45,316 |
| Elekta AB (publ) | 4,718 |
| AddLife AB (publ) | 2,301 |
Hansa Biopharma AB News
- 4 days ago - Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome - PRNewsWire
- 16 days ago - Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease - PRNewsWire
- 18 days ago - Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome - Business Wire
- 19 days ago - Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome - PRNewsWire
- 7 weeks ago - Hansa Biopharma to Attend Truist Securities BioPharma Symposium - PRNewsWire
- 2 months ago - Hansa Biopharma AB (publ) (HNSBF) Q3 2024 Results Conference Call Transcript - Seeking Alpha
- 2 months ago - Hansa Biopharma AB (publ) 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results - PRNewsWire